Related Experiment Videos
Biological prognostic and predictive factors in lung cancer
Antonio Rossi1, Domenico Galetta, Cesare Gridelli
1Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy. arossi_it@yahoo.it
Abstract:
The inclusion of new drugs in clinical research and practice has allowed improvements in several outcomes of advanced non-small-cell lung cancer (NSCLC). Among these drugs, very interesting results have been obtained from pemetrexed and new targeted agents, including the inhibitors of epidermal growth factor receptor (EGFR) such as gefitinib, erlotinib and cetuximab. Unfortunately, these new drugs when investigated for the treatment of small-cell lung cancer (SCLC) reported negative results. The results of these investigations seem to be related to specific factors that could indicate which patients could benefit from each specific therapy. Therefore, several clinical and biological factors might find use as prognostic or predictive markers. A prognostic factor provides information on outcome, independent of the therapy that is used. In contrast, a predictive factor provides information on outcome with regard to a specific therapy. Some factors, such as EGFR mutations, are both prognostic and predictive. In the present paper, we review data related to thymidylate synthase, EGFR and K-ras mutations, the most important biologic prognostic and/or predictive factors related to pemetrexed, gefitinib, erlotinib and cetuximab therapy in the treatment of advanced NSCLC and in SCLC patients.
Insights
New targeted therapies show promise for advanced non-small-cell lung cancer (NSCLC) but not small-cell lung cancer (SCLC). Biomarkers like EGFR mutations predict treatment response in NSCLC patients.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Advanced non-small-cell lung cancer (NSCLC) outcomes have improved with new drugs.
- Targeted agents, including epidermal growth factor receptor (EGFR) inhibitors (gefitinib, erlotinib, cetuximab), show promise in NSCLC.
- These agents have yielded negative results in small-cell lung cancer (SCLC) trials.
Purpose of the Study:
- To review prognostic and predictive biomarkers for advanced NSCLC and SCLC.
- To analyze the role of thymidylate synthase, EGFR, and K-ras mutations in treatment selection.
- To understand patient stratification for pemetrexed, gefitinib, erlotinib, and cetuximab therapies.
Main Methods:
- Review of clinical research data on pemetrexed and targeted therapies in NSCLC and SCLC.
- Analysis of biological factors including thymidylate synthase, EGFR mutations, and K-ras mutations.
- Evaluation of prognostic versus predictive marker definitions and applications.
Main Results:
- EGFR mutations are both prognostic and predictive in NSCLC treatment.
- Specific biological factors correlate with patient response to targeted therapies in NSCLC.
- Current targeted agents show limited efficacy in SCLC, suggesting different underlying mechanisms.
Conclusions:
- Biomarkers are crucial for personalizing lung cancer treatment, particularly for advanced NSCLC.
- EGFR and K-ras mutations, along with thymidylate synthase status, are key predictive factors for targeted therapies.
- Further research is needed to identify effective treatments for SCLC based on distinct biological profiles.